LENZ Therapeutics, Inc.
LENZ
$4.73
$0.132.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 329.50% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 329.50% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 294.02% | -- | -- | -- | -- |
| SG&A Expenses | 281.20% | 263.64% | 216.35% | 144.38% | 86.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 134.67% | 134.35% | 88.07% | 24.90% | -11.07% |
| Operating Income | -118.95% | -99.05% | -55.50% | 0.69% | 17.71% |
| Income Before Tax | -142.78% | -127.26% | -64.01% | 4.27% | 25.49% |
| Income Tax Expenses | -99.00% | 50,100.00% | 50,100.00% | 379.89% | 379.89% |
| Earnings from Continuing Operations | -140.47% | -128.31% | -65.02% | 3.17% | 24.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -140.47% | -128.31% | -65.02% | 3.17% | 24.58% |
| EBIT | -118.95% | -99.05% | -55.50% | 0.69% | 17.71% |
| EBITDA | -118.54% | -98.74% | -55.16% | 0.94% | 17.80% |
| EPS Basic | -114.98% | -103.37% | 41.19% | 87.11% | 92.58% |
| Normalized Basic EPS | -116.18% | -97.10% | 42.03% | 87.28% | 92.67% |
| EPS Diluted | -114.98% | -103.37% | 41.19% | 87.11% | 92.58% |
| Normalized Diluted EPS | -116.18% | -97.10% | 42.03% | 87.28% | 92.67% |
| Average Basic Shares Outstanding | 10.94% | 10.43% | 35.56% | 87.73% | 221.90% |
| Average Diluted Shares Outstanding | 10.94% | 10.43% | 35.56% | 87.73% | 221.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |